Neurology Central

Overcoming the blood-brain barrier to treat Parkinson’s disease

A novel drug delivery system that bypasses the blood-brain barrier (BBB) will be used in combination with Herantis Pharma Plc’s (Helsinki, Finland) drug candidate CDNF for the treatment of Parkinson’s disease (PD) in upcoming Phase I-II clinical trials. The study will be supported by a €6 million Horizon 2020 grant, an innovation from the European Union.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.